TITLE

Interferon â treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology

AUTHOR(S)
Filippi, M.; Rovaris, M.; Capra, R.; Gasperini, C.; Prandini, F.; Martinelli, V.; Horsfield, M. A.; Bastianello, S.; Sormani, M. P.; Pozzilli, C.; Comi, G.
PUB. DATE
September 1999
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Sep1999, p386
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66650186

 

Related Articles

  • Around the globe.  // European Radiology;May2000, Vol. 10 Issue 5, p874 

    The article presents news related to medical radiology. The association between brain atrophy and permanent functional deficits in multiple sclerosis and the temporal relation between atrophy and the clinical disease course have seldom been investigated. The ability of recombinant human...

  • The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. Koch-Henriksen, N.; Soelberg Sørensen, P. // Multiple Sclerosis (13524585);Jun2000, Vol. 6 Issue 3, p172 

    After approval by the European Union in 1996 of interferon-beta for treatment of relapsing-remitting multiple sclerosis (RRMS), 862 patients in Denmark have received treatment (by April 1999), and 304 of those were enrolled into an open labelled randomised trial to compare the efficacy and...

  • Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge. Kalanie, Hossein; Harandi, Ali Amini; Bakhshandehpour, Reza; Heidari, Daryoosh // Case Reports in Radiology;2012, p1 

    Tumefactive demyelinating lesion is defined as large solitary demyelinating lesion with imaging characteristics mimicking neoplasm. These atypical features include size more than 2 cm, mass effect, edema, and/or ring enhancement. Distinguishing tumefactive lesions from other etiologies of...

  • MS and infections.  // Multiple Sclerosis Journal;Sep2013 Supplement, p394 

    The article presents several abstracts related to multiple sclerosis (MS) including the articles "Fine specificity of the B cell response to Epstein-Barr nuclear antigen 1," by R. Mechelli and colleagues, "Measures of Epstein-Barr virus activity correlate with enhancing lesions on MRI in...

  • Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Pulicken, M.; Bash, C. N.; Costello, K.; Said, A.; Cuffari, C.; Wilterdink, J. L.; Rogg, J. M.; Mills, P.; Calabresi, P. A. // Multiple Sclerosis (13524585);Apr2005, Vol. 11 Issue 2, p169 

    We conducted an open-label pilot clinical trial to evaluate the safety and efficacy of adding oral azathioprine to the treatment regimen of 15 multiple sclerosis patients breaking through monotherapy with interferon β-1b. There were no serious adverse events. Gastrointestinal side effects and...

  • Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Nortvedt, M.W.; Riise, T.; Myhr, K.M.; Nyland, H.I.; Hanestad, B.R. // Multiple Sclerosis (13524585);Oct99, Vol. 5 Issue 5, p317 

    The objective of the study was to examine whether the beneficial effect of treatment of interferon alfa-2a on multiple sclerosis seen by magnetic resonance imaging is reflected in a corresponding improvement in the quality of life (QoL) and to address the impact of adverse events related to this...

  • Therapeutical dilemmas in patients with multiple sclerosis. Rallis, D.; Roussopoulou, A.; Skafida, A.; Kalaitzaki, S.; Katsoulakou, S. // Scientific Chronicles / Epistimonika Chronika;Jan2013, p13 

    The therapeutic armamentarium in Multiple Sclerosis (MS) has increased considerably during the past years. Neurologists often face dilemmas in their effort to select the proper therapeutic agent. Considering the long-lasting experience and well-established profile of safety, interferon-ß is...

  • CMSC Recommends Adding MRI to Clinical Classification of MS. Greb, Erik // Neurology Reviews;Dec2012, Vol. 20 Issue 12, p1 

    The article informs that the professional organization Consortium of Multiple Sclerosis Centers (CMSC) advocates the application of magnetic resonance imaging (MRI) gadolinium-enhancing (Gd+) T1-weighted lesions in clinical classification of multiple sclerosis (MS). It mentions that CMSC has...

  • Bench to Bedside: Tempering antigen-presenting cells in multiple sclerosis. Prod'homme, Thomas; Zamvil, Scott S. // Nature Medicine;Jun2008, Vol. 14 Issue 6, p614 

    The article presents a study on the effectiveness of Interferon-β (IFN-β) as a treatment for multiple sclerosis. In multiple sclerosis IFN-β is known to suppress development of inflammatory lesions in the brain as detected by magnetic resonance imaging (MRI). This suppression is...

  • Identifying responders and nonresponders to interferon therapy in multiple sclerosis. Prosperini, Luca; Capobianco, Marco; Giannì, Costanza // Degenerative Neurological & Neuromuscular Disease;2014, Vol. 4, p75 

    Interferon beta is a well established disease-modifying agent used for relapsing-remitting multiple sclerosis. Despite treatment, a relevant proportion of patients continue to experience clinical (ie, relapses, worsening of disability) and magnetic resonance imaging (MRI) activity. Early...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics